buspirone has been researched along with citalopram in 53 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (20.75) | 18.2507 |
| 2000's | 19 (35.85) | 29.6817 |
| 2010's | 20 (37.74) | 24.3611 |
| 2020's | 3 (5.66) | 2.80 |
| Authors | Studies |
|---|---|
| Carrupt, PA; Gaillard, P; Schambel, P; Testa, B | 1 |
| Bergström, F; Giordanetto, F; Rehngren, M; Tunek, A; Wan, H | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Sen, S; Sinha, N | 1 |
| Chang, G; Di, L; Huang, Y; Lin, Z; Liston, TE; Scott, DO; Troutman, MD; Umland, JP | 1 |
| Bang-Andersen, B; Frederiksen, K; Hogg, S; Jensen, KG; Jørgensen, M; Mørk, A; Nielsen, SM; Ruhland, T; Smith, G; Stensbøl, TB; Zhong, H | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Meert, TF | 1 |
| Druse, MJ; Kim, JA | 1 |
| Hjorth, S | 1 |
| Ikeda, Y; Itoyama, Y; Izumi, J; Kato, H; Kogure, K; Nakata, N; Suda, H; Tanaka, Y | 1 |
| Adielsson, G; Spigset, O | 1 |
| Allikmets, L; Matto, V; Skrebuhhova, T | 1 |
| Bourin, M; Redrobe, JP | 1 |
| Bejerot, S; Bodlund, O | 1 |
| Agren, H; Björling, G; Fahlén, T; Landén, M | 1 |
| Agren, H; Eriksson, E; Fahlén, T; Landén, M | 1 |
| Terao, T | 1 |
| Wise, M | 1 |
| Lantz, MS | 1 |
| Appelberg, BG; Koskinen, TE; Mehtonen, OP; Muhonen, TT; Naukkarinen, HH; Syvälahti, EK | 1 |
| Högberg, P; Landén, M; Thase, ME | 1 |
| Hietala, J; Laakso, A; Majasuo, H; Pälvimäki, EP; Penttilä, J; Syvälahti, E | 1 |
| Biggs, MM; Fava, M; Lebowitz, BD; Luther, JF; Nierenberg, AA; Quitkin, F; Ritz, L; Rush, AJ; Shores-Wilson, K; Thase, ME; Trivedi, MH; Warden, D; Wisniewski, SR | 1 |
| Williams, SC | 1 |
| Gastó, C; Gómez-Gil, E; Imaz, ML; Martín-Santos, R; Martínez de Osaba, MJ; Navinés, R | 1 |
| Biggs, MM; Fava, M; Friedman, ES; Hollon, SD; Luther, JF; McGrath, PJ; Niederehe, G; Nierenberg, AA; Rush, AJ; Thase, ME; Trivedi, MH; Warden, D; Wisniewski, SR | 1 |
| Shelton, RC | 1 |
| Balasubramani, GK; Kornstein, SG; Lesser, IM; Nierenberg, AA; Preskorn, SH; Rush, AJ; Shores-Wilson, K; Thase, ME; Trivedi, MH; Warden, D; Wisniewski, SR; Young, EA | 1 |
| Gastó, C; Gómez-Gil, E; Martín-Santos, R; Martínez de Osaba, MJ; Navinés, R | 1 |
| Pollack, MH | 1 |
| Chuzi, SE; Fava, M; Papakostas, GI; Sousa, JL | 1 |
| Laje, G; McMahon, FJ; Perlis, RH; Rush, AJ | 1 |
| Aziz-Mohammadi, M; Blokland, A; Lim, LW; Schruers, K; Sesia, T; Steinbusch, HW; Tan, S; Temel, Y; Visser-Vandewalle, V; Vlamings, R | 1 |
| Aziz-Mohammadi, M; Blokland, A; Jahanshahi, A; Janssen, M; Lim, LW; Schruers, K; Steinbusch, HW; Tan, S; Temel, Y; van Duinen, M; Visser-Vandewalle, V; Vlamings, R | 1 |
| Bech, P; Fava, M; Rush, AJ; Trivedi, MH; Wisniewski, SR | 1 |
| Dusetzina, SB; Ellis, AR; Farley, JF; Gaynes, BN; Hansen, RA; Miller, WC; Stürmer, T | 1 |
| Fava, M; Perlis, RH; Perroud, N; Uher, R | 1 |
| Blokland, A; Hestermann, D; Lim, LW; Temel, Y | 1 |
| Bishop, C; Conti, MM; Lindenbach, D; Ostock, CY; Palumbo, N; Vilceus, N | 1 |
| Marston, HM; Mitchell, EN; Nutt, DJ; Phelps, CE; Robinson, ES | 1 |
| Bonan, CD; Lara, DR; Piato, AL; Schaefer, IC; Siebel, AM; Vianna, MR | 1 |
| Aquili, L; Blokland, A; Chan, AY; Lim, LW; Lim, WL; Mok, ATC; Perucho, JAU; Tan, SZK; Temel, Y | 1 |
| Botas, JL; Nunes, JC | 1 |
| Boecxstaens, V; Broers, C; Geeraerts, A; Geysen, H; Pauwels, A; Peersman, N; Tack, J; Van Houtte, B; Vanuytsel, T; Vermeersch, P | 1 |
2 review(s) available for buspirone and citalopram
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Refractory generalized anxiety disorder.
Topics: Anti-Anxiety Agents; Anticonvulsants; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Anxiety Disorders; Azabicyclo Compounds; Benzodiazepines; Buspirone; Chronic Disease; Citalopram; Cognitive Behavioral Therapy; Comorbidity; Diagnosis, Differential; Drug Therapy, Combination; Eszopiclone; Humans; Mental Health Services; Neurobiology; Neuroprotective Agents; Piperazines; Prevalence; Recurrence; Riluzole; Selective Serotonin Reuptake Inhibitors; United States | 2009 |
13 trial(s) available for buspirone and citalopram
| Article | Year |
|---|---|
A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression.
Topics: Adult; Aged; Buspirone; Citalopram; Depressive Disorder; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paroxetine; Placebo Effect; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Treatment Outcome | 1998 |
Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors.
Topics: Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Buspirone; Citalopram; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunctions, Psychological | 1999 |
Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study.
Topics: Adult; Aged; Ambulatory Care; Buspirone; Citalopram; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Finland; Fluoxetine; Humans; Male; Middle Aged; Patient Dropouts; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Severity of Illness Index; Single-Blind Method; Treatment Outcome | 2001 |
Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine.
Topics: Buspirone; Citalopram; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Incidence; Male; Middle Aged; Norway; Paroxetine; Placebos; Psychiatric Status Rating Scales; Reproducibility of Results; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Sexual Dysfunctions, Psychological; Surveys and Questionnaires; Sweden | 2005 |
Medication augmentation after the failure of SSRIs for depression.
Topics: Adult; Bupropion; Buspirone; Citalopram; Delayed-Action Preparations; Depressive Disorder, Major; Dopamine Uptake Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Logistic Models; Male; Remission Induction; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Treatment Failure | 2006 |
Effects of citalopram treatment on hypothermic and hormonal responses to the 5-HT1A receptor agonist buspirone in patients with major depression and therapeutic response.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Buspirone; Citalopram; Depressive Disorder, Major; Female; Humans; Hydrocortisone; Hypothermia; Male; Middle Aged; Prolactin; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Agonists; Treatment Outcome | 2007 |
Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report.
Topics: Adult; Ambulatory Care; Antidepressive Agents; Bupropion; Buspirone; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cross-Over Studies; Cyclohexanols; Decision Trees; Delayed-Action Preparations; Depressive Disorder, Major; Female; Humans; Male; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Treatment Outcome; Venlafaxine Hydrochloride | 2007 |
What predicts attrition in second step medication treatments for depression?: a STAR*D Report.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Bupropion; Buspirone; Citalopram; Data Interpretation, Statistical; Depressive Disorder, Major; Drug Therapy, Combination; Female; Forecasting; Humans; Male; Middle Aged; Outpatients; Patient Dropouts; Prospective Studies; Psychiatric Status Rating Scales; Quality of Life; Serotonin Receptor Agonists; Socioeconomic Factors; Young Adult | 2009 |
Interaction between serotonin 5-HT1A receptors and beta-endorphins modulates antidepressant response.
Topics: Adolescent; Adult; beta-Endorphin; Buspirone; Case-Control Studies; Citalopram; Depressive Disorder, Major; Female; Humans; Immunoradiometric Assay; Male; Middle Aged; Receptor, Serotonin, 5-HT1A; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Severity of Illness Index; Statistics, Nonparametric; Time Factors; Young Adult | 2008 |
5HT1A-mediated stimulation of cortisol release in major depression: use of non-invasive cortisol measurements to predict clinical response.
Topics: Adolescent; Adult; Aged; Buspirone; Citalopram; Depressive Disorder, Major; Female; Follow-Up Studies; Humans; Hydrocortisone; Logistic Models; Male; Middle Aged; Psychiatric Status Rating Scales; Radioimmunoassay; Saliva; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Young Adult | 2010 |
Pharmacogenetics studies in STAR*D: strengths, limitations, and results.
Topics: Adult; Biomarkers; Bupropion; Buspirone; Citalopram; Cognitive Behavioral Therapy; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Dopamine Uptake Inhibitors; Humans; Pharmacogenetics; Phenotype; Polymorphism, Single Nucleotide; Receptor, Serotonin, 5-HT2A; Receptors, Kainic Acid; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Serotonin Receptor Agonists; Sertraline; Treatment Failure; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Bupropion; Buspirone; Citalopram; Delayed-Action Preparations; Depressive Disorder, Major; Humans; Middle Aged; Quality of Life; Treatment Outcome | 2012 |
Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Bupropion; Buspirone; Citalopram; Cyclohexanols; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Female; Humans; Likelihood Functions; Male; Middle Aged; Personality Inventory; Psychometrics; Quality of Life; Sertraline; United States; Venlafaxine Hydrochloride; Young Adult | 2012 |
38 other study(ies) available for buspirone and citalopram
| Article | Year |
|---|---|
Binding of arylpiperazines, (aryloxy)propanolamines, and tetrahydropyridylindoles to the 5-HT1A receptor: contribution of the molecular lipophilicity potential to three-dimensional quantitative structure-affinity relationship models.
Topics: Indoles; Ligands; Models, Molecular; Molecular Conformation; Molecular Structure; Piperazines; Propanolamines; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Serotonin; Structure-Activity Relationship; Tetrahydronaphthalenes | 1996 |
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
Topics: Animals; Brain; Central Nervous System Agents; Dialysis; Hydrophobic and Hydrophilic Interactions; In Vitro Techniques; Mice; Models, Statistical; Protein Binding; Quantitative Structure-Activity Relationship; Rats | 2007 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Species independence in brain tissue binding using brain homogenates.
Topics: Animals; Brain; Dogs; Guinea Pigs; Humans; Macaca fascicularis; Mice; Rats; Species Specificity | 2011 |
Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.
Topics: Animals; Antidepressive Agents; Cell Line; Depressive Disorder, Major; Drug Partial Agonism; Drug Stability; Hippocampus; Humans; In Vitro Techniques; Microsomes, Liver; Oocytes; Piperazines; Radioligand Assay; Rats; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Receptors, Serotonin, 5-HT3; Recombinant Proteins; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT3 Receptor Antagonists; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship; Sulfides; Vortioxetine; Xenopus | 2011 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Effects of various serotonergic agents on alcohol intake and alcohol preference in Wistar rats selected at two different levels of alcohol preference.
Topics: Alcohol Drinking; Alcoholism; Animals; Buspirone; Chlordiazepoxide; Citalopram; Dose-Response Relationship, Drug; Drinking; Fluoxetine; Male; Ondansetron; Rats; Receptors, Serotonin; Ritanserin; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists | 1993 |
Protective effects of maternal buspirone treatment on serotonin reuptake sites in ethanol-exposed offspring.
Topics: Animals; Autoradiography; Brain; Brain Chemistry; Buspirone; Central Nervous System Depressants; Citalopram; Ethanol; Female; Fetal Alcohol Spectrum Disorders; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Weight Gain | 1996 |
(-)-Pindolol, but not buspirone, potentiates the citalopram-induced rise in extracellular 5-hydroxytryptamine.
Topics: Animals; Buspirone; Citalopram; Drug Synergism; Hippocampus; Male; Pindolol; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Receptor Agonists | 1996 |
Role of hippocampal serotonergic neurons in ischemic neuronal death.
Topics: 5,7-Dihydroxytryptamine; Animals; Brain Ischemia; Buspirone; Carotid Arteries; Cell Death; Citalopram; Gerbillinae; Hippocampus; Injections; Male; Neurons; Piperazines; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Agents; Serotonin Antagonists; Serotonin Receptor Agonists | 1997 |
Combined serotonin syndrome and hyponatraemia caused by a citalopram-buspirone interaction.
Topics: Aged; Buspirone; Citalopram; Depressive Disorder; Drug Interactions; Female; Humans; Hyponatremia; Mental Disorders; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Receptor Agonists | 1997 |
Apomorphine-induced aggressiveness and [3H]citalopram binding after antidepressant treatment in rats.
Topics: Aggression; Animals; Antidepressive Agents; Apomorphine; Behavior, Animal; Binding Sites; Buspirone; Citalopram; Dopamine Agonists; Male; Posture; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists | 1998 |
Dose-dependent influence of buspirone on the activities of selective serotonin reuptake inhibitors in the mouse forced swimming test.
Topics: Animals; Antidepressive Agents; Buspirone; Citalopram; Depression; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Exercise Test; Fluoxetine; Fluvoxamine; Male; Mice; Motor Activity; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Swimming | 1998 |
Response to high doses of citalopram in treatment-resistant obsessive-compulsive disorder.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Buspirone; Citalopram; Clomipramine; Delusions; Drug Resistance; Female; Flupenthixol; Humans; Obsessive-Compulsive Disorder; Recurrence; Treatment Outcome | 1998 |
Female sexual dysfunction and antidepressant use.
Topics: Amantadine; Antidepressive Agents; Buspirone; Citalopram; Depressive Disorder; Drug Therapy, Combination; Female; Fluoxetine; Humans; Meta-Analysis as Topic; Paroxetine; Personality Inventory; Placebos; Sexual Dysfunctions, Psychological; Treatment Outcome | 2001 |
Citalopram-induced bruxism.
Topics: Buspirone; Citalopram; Humans; Male; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Sleep Bruxism | 2001 |
Serotonin syndrome. A common but often unrecognized psychiatric condition.
Topics: Aged; Anxiety Disorders; Buspirone; Citalopram; Depression; Female; Humans; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome; Trazodone | 2001 |
Combined treatment with citalopram and buspirone: effects on serotonin 5-HT2A and 5-HT2C receptors in the rat brain.
Topics: Amphetamines; Animals; Anti-Anxiety Agents; Antidepressive Agents; Autoradiography; Brain Chemistry; Buspirone; Cerebral Cortex; Choroid Plexus; Citalopram; Ergolines; Hydrolysis; Image Processing, Computer-Assisted; Ketanserin; Male; Phosphatidylinositols; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Serotonin Antagonists | 2006 |
Depression--augmentation or switch after initial SSRI treatment.
Topics: Bupropion; Buspirone; Citalopram; Delayed-Action Preparations; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Placebo Effect; Remission Induction; Research Design; Selective Serotonin Reuptake Inhibitors | 2006 |
Augmentation strategies to increase antidepressant efficacy.
Topics: Algorithms; Bupropion; Buspirone; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Drug Synergism; Humans; Remission Induction; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Sertraline | 2007 |
Attenuation of fear-like response by escitalopram treatment after electrical stimulation of the midbrain dorsolateral periaqueductal gray.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Buspirone; Citalopram; Deep Brain Stimulation; Escape Reaction; Exploratory Behavior; Fear; Locomotion; Male; Periaqueductal Gray; Random Allocation; Rats; Rats, Wistar | 2010 |
Increased plasma corticosterone levels after periaqueductal gray stimulation-induced escape reaction or panic attacks in rats.
Topics: Analysis of Variance; Animals; Anti-Anxiety Agents; Buspirone; Citalopram; Corticosterone; Electric Stimulation; Escape Reaction; Fluorescent Antibody Technique; Male; Neurons; Panic; Periaqueductal Gray; Proto-Oncogene Proteins c-fos; Radioimmunoassay; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors | 2011 |
Do suicidal thoughts or behaviors recur during a second antidepressant treatment trial?
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Buspirone; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Substitution; Drug Therapy, Combination; Female; Humans; Intention; Male; Middle Aged; Multicenter Studies as Topic; Odds Ratio; Personality Inventory; Primary Health Care; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; Risk Factors; Sertraline; Suicidal Ideation; Suicide, Attempted; Thinking; Venlafaxine Hydrochloride | 2012 |
Acute serotonergic treatment changes the relation between anxiety and HPA-axis functioning and periaqueductal gray activation.
Topics: Animals; Anxiety; Buspirone; Citalopram; Corticosterone; Hypothalamo-Hypophyseal System; Male; Motor Activity; Periaqueductal Gray; Pituitary-Adrenal System; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Serotonin Agents; Serotonin Receptor Agonists | 2014 |
Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Buspirone; Citalopram; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinson Disease; Psychomotor Performance; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Agonists | 2015 |
Psychopharmacological characterisation of the successive negative contrast effect in rats.
Topics: Amphetamine; Animals; Anti-Anxiety Agents; Behavior, Animal; Buspirone; Carbolines; Citalopram; Diazepam; Dopamine Agents; Dopamine Antagonists; Emotions; Flupenthixol; GABA Antagonists; Male; Rats; Reward; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists | 2015 |
The side-by-side exploratory test: a simple automated protocol for the evaluation of adult zebrafish behavior simultaneously with social interaction.
Topics: Animals; Bromazepam; Buspirone; Citalopram; Clonazepam; Dose-Response Relationship, Drug; Exploratory Behavior; Fear; Female; Fluoxetine; Male; Pattern Recognition, Automated; Psychological Tests; Psychotropic Drugs; Social Behavior; Software; Stress, Psychological; Vision, Ocular; Zebrafish | 2015 |
Serotonergic treatment normalizes midbrain dopaminergic neuron increase after periaqueductal gray stimulation.
Topics: Animals; Buspirone; Citalopram; Deep Brain Stimulation; Dopaminergic Neurons; Electric Stimulation; Fear; Freezing Reaction, Cataleptic; Male; Mesencephalon; Periaqueductal Gray; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists | 2020 |
A Serotonin "Cocktail".
Topics: Buspirone; Citalopram; Depression; Drug Therapy, Combination; Female; Humans; Middle Aged; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Serotonin Syndrome | 2020 |
The role of serotonin in the control of esophageal sensitivity assessed by multimodal stimulation in health.
Topics: Adult; Buspirone; Citalopram; Esophagus; Female; Gastroesophageal Reflux; Healthy Volunteers; Humans; Male; Middle Aged; Pain Threshold; Physical Stimulation; Proof of Concept Study; Selective Serotonin Reuptake Inhibitors; Sensory Thresholds; Serotonin; Serotonin Receptor Agonists; Tryptophan; Young Adult | 2021 |